These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 33105030)

  • 1. Real-world, population-based cohort study of toxicity and resource utilization of second-line ipilimumab for metastatic melanoma in Ontario, Canada.
    Dai WF; Beca J; Croxford R; Isaranuwatchai W; Menjak IB; Petrella TM; Mittmann N; Earle CC; Gavura S; Mercer RE; Hanna TP; Chan KKW
    Int J Cancer; 2021 Apr; 148(8):1910-1918. PubMed ID: 33105030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada.
    Dai WF; Beca JM; Croxford R; Isaranawatchai W; Menjak IB; Petrella TM; Mittmann N; Earle CC; Gavura S; Hanna TP; Chan KKW
    BMC Cancer; 2020 Apr; 20(1):304. PubMed ID: 32293341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab versus ipilimumab plus nivolumab in US academic centers.
    Joseph RW; Shillington AC; Lee TA; Macahilig CP; Diede SJ; Dave V; Harshaw Q; Scherrer E; Liu FX
    J Med Econ; 2020 Feb; 23(2):132-138. PubMed ID: 31750751
    [No Abstract]   [Full Text] [Related]  

  • 4. Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study).
    McArthur GA; Mohr P; Ascierto PA; Arance A; Banos Hernaez A; Kaskel P; Weichenthal M; Shinde R; Stevinson K
    Oncologist; 2017 Aug; 22(8):951-962. PubMed ID: 28526721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world evidence for option value in metastatic melanoma.
    Wong WB; To TM; Li M; Lee W; Veenstra DL; Garrison LP
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1546-1555. PubMed ID: 34431715
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.
    Luke JJ; Callahan MK; Postow MA; Romano E; Ramaiya N; Bluth M; Giobbie-Hurder A; Lawrence DP; Ibrahim N; Ott PA; Flaherty KT; Sullivan RJ; Harding JJ; D'Angelo S; Dickson M; Schwartz GK; Chapman PB; Wolchok JD; Hodi FS; Carvajal RD
    Cancer; 2013 Oct; 119(20):3687-95. PubMed ID: 23913718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study.
    Middleton MR; Dalle S; Claveau J; Mut P; Hallmeyer S; Plantin P; Highley M; Kotapati S; Le TK; Brokaw J; Abernethy AP
    Cancer Med; 2016 Jul; 5(7):1436-43. PubMed ID: 27118102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A population-based study of the treatment effect of first-line ipilimumab for metastatic or unresectable melanoma.
    Drysdale E; Peng Y; Nguyen P; Baetz T; Hanna TP
    Melanoma Res; 2019 Dec; 29(6):635-642. PubMed ID: 30789386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma.
    Ascierto PA; Del Vecchio M; Mackiewicz A; Robert C; Chiarion-Sileni V; Arance A; Lebbé C; Svane IM; McNeil C; Rutkowski P; Loquai C; Mortier L; Hamid O; Bastholt L; Dreno B; Schadendorf D; Garbe C; Nyakas M; Grob JJ; Thomas L; Liszkay G; Smylie M; Hoeller C; Ferraresi V; Grange F; Gutzmer R; Pikiel J; Hosein F; Simsek B; Maio M
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
    Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
    JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands.
    Jochems A; Leeneman B; Franken MG; Schouwenburg MG; Aarts MJB; van Akkooi ACJ; van den Berkmortel FWPJ; van den Eertwegh AJM; Groenewegen G; de Groot JWB; Haanen JBAG; Hospers GAP; Kapiteijn E; Koornstra RH; Kruit WHJ; Louwman MWJ; Piersma D; van Rijn RS; Ten Tije AJ; Vreugdenhil G; Wouters MWJM; Uyl-de Groot CA; van der Hoeven KJM
    Anticancer Drugs; 2018 Jul; 29(6):572-578. PubMed ID: 29659371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab.
    Mohr P; Ascierto P; Arance A; McArthur G; Hernaez A; Kaskel P; Shinde R; Stevinson K
    J Eur Acad Dermatol Venereol; 2018 Jun; 32(6):962-971. PubMed ID: 29044660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
    Kreft S; Gesierich A; Eigentler T; Franklin C; Valpione S; Ugurel S; Utikal J; Haferkamp S; Blank C; Larkin J; Garbe C; Schadendorf D; Lorigan P; Schilling B
    Eur J Cancer; 2019 Jul; 116():207-215. PubMed ID: 31212163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastatic melanoma patient outcomes since introduction of immune checkpoint inhibitors in England between 2014 and 2018.
    Board R; Smittenaar R; Lawton S; Liu H; Juwa B; Chao D; Corrie P
    Int J Cancer; 2021 Feb; 148(4):868-875. PubMed ID: 32838478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade.
    Bello DM; Panageas KS; Hollmann T; Shoushtari AN; Momtaz P; Chapman PB; Postow MA; Callahan MK; Wolchok JD; Brady MS; Coit DG; Ariyan CE
    Ann Surg Oncol; 2020 Apr; 27(4):1180-1188. PubMed ID: 31848819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of second-line ipilimumab for metastatic melanoma: A real-world population-based cohort study of resource utilization.
    Lu B; Dai WF; Croxford R; Isaranuwatchai W; Beca J; Menjak IB; Petrella TM; Mittmann N; Earle CC; Gavura S; Mercer RE; Hanna TP; Chan KKW
    Cancer Med; 2023 May; 12(10):11451-11461. PubMed ID: 36999965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-dependent toxicity of ipilimumab in metastatic melanoma.
    Olischewsky A; De Schrijver S; Bankfalvi A; Wetter A; Zimmer L; Livingstone E; Schadendorf D; Ugurel S
    Eur J Cancer; 2018 May; 95():104-108. PubMed ID: 29477367
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of a Multidisciplinary Immunotherapy Toxicity Monitoring Program for Patients Receiving Ipilimumab for Metastatic Melanoma.
    Menjak IB; Elias ES; Jain S; Lawrie D; Petrella TM
    JCO Oncol Pract; 2021 Nov; 17(11):e1631-e1638. PubMed ID: 33780266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential immunotherapy in melanoma: is it a realistic alternative to dual immunotherapy?
    Wilson T; Taylor H; Winter H; Herbert C
    Melanoma Res; 2021 Aug; 31(4):366-370. PubMed ID: 34039944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
    Schachter J; Ribas A; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank C; Petrella TM; Hamid O; Zhou H; Ebbinghaus S; Ibrahim N; Robert C
    Lancet; 2017 Oct; 390(10105):1853-1862. PubMed ID: 28822576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.